Dermatology Cream Franchise in Ahmedabad

Antifungal Combination Cream Supplier in Mumbai

Skin Infection Treatment Cream Distributor in Delhi

Dermatology Product Manufacturer in Bangalore

Antibacterial Antifungal Cream Stockist in Hyderabad
Dermatology Medicine Exporter in Chandigarh

Home/Products /ofloxacin-0-point-75-w-w-ornidazole-2-w-w-itraconazole-1-w-w-clobetasol-0-point-05-w-w-cream

Diziderm IT Cream

Composition : Ofloxacin (0.75% w/w) + Ornidazole (2% w/w) + Itraconazole (1% w/w) + Clobetasol (0.05% w/w) Cream

Dosage Form : Cream

Packaging Type : Tube

Packaging : 15gm

Price : ₹99/-

Ofloxacin + Ornidazole + Itraconazole + Clobetasol Cream is indicated for the management of mixed skin infections involving bacterial, fungal, and inflammatory components, commonly seen in dermatological conditions with redness and itching.

Ofloxacin provides broad-spectrum antibacterial coverage, ornidazole targets anaerobic microorganisms, itraconazole acts as a potent antifungal agent, and clobetasol helps control severe inflammation, itching, and erythema.

This combination is commonly prescribed in infected dermatitis, fungal infections with secondary bacterial involvement, eczema with infection, and inflammatory dermatoses, where multi-action therapy ensures faster symptom relief.

With strong therapeutic coverage, visible clinical results, and wide dermatology acceptance, this formulation supports repeat demand, builds prescriber confidence, and helps expand customer reach through effective management of common and recurrent skin infections.

Read More

About the Product

Ofloxacin + Ornidazole + Itraconazole + Clobetasol Cream is indicated for the management of mixed skin infections involving bacterial, fungal, and inflammatory components, commonly seen in dermatological conditions with redness and itching.

Ofloxacin provides broad-spectrum antibacterial coverage, ornidazole targets anaerobic microorganisms, itraconazole acts as a potent antifungal agent, and clobetasol helps control severe inflammation, itching, and erythema.

This combination is commonly prescribed in infected dermatitis, fungal infections with secondary bacterial involvement, eczema with infection, and inflammatory dermatoses, where multi-action therapy ensures faster symptom relief.

With strong therapeutic coverage, visible clinical results, and wide dermatology acceptance, this formulation supports repeat demand, builds prescriber confidence, and helps expand customer reach through effective management of common and recurrent skin infections.

Common side effects may include mild burning sensation, itching, redness, dryness, or irritation at the application site. Prolonged use may cause skin thinning, discoloration, or steroid-related effects.

Diziderm IT Cream is indicated for the treatment of fungal skin infections with secondary bacterial involvement, including dermatophytosis, candidiasis, tinea infections, infected eczema, and inflammatory dermatoses as advised by a healthcare professional.

For external use only. Apply a thin layer to the affected area as prescribed. Avoid prolonged use, especially on the face, groin, or broken skin. Discontinue use and consult a doctor if irritation, worsening of symptoms, or adverse reactions occur.

Store below 25°C in a cool, dry place. Protect from direct sunlight. Keep the tube tightly closed and out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation